In this case, the calculation is based on 60 companies, 20%. That would be $60 million, if we look at the amount of research invested by these 60 biotech companies in Canada.
October 25th, 2006 / 10:25 a.m.
President and Chief Executive Officer, Aeterna Zentaris Inc., Canada's Research-Based Pharmaceutical Companies (Rx&D)
In this case, the calculation is based on 60 companies, 20%. That would be $60 million, if we look at the amount of research invested by these 60 biotech companies in Canada.
See context to find out what was said next.